Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease
-
- Kumi Oshima
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Miki Sato
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Shinya Okuda
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Kiriko Terasako
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Hideki Nakasone
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Shinichi Kako
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Rie Yamazaki
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Yukie Tanaka
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Aki Tanihara
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Takakazu Higuchi
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Junji Nishida
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Ikuo Nakamura
- Division of GastroenterologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Yukio Yoshida
- Division of GastroenterologySaitama Medical Center, Jichi Medical University, Saitama, Japan
-
- Yoshinobu Kanda
- Division of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan
書誌事項
- 公開日
- 2009-04
- DOI
-
- 10.1179/102453309x385223
- 公開者
- Informa UK Limited
説明
The appearance of hepatitis B surface antigen (HBsAg) in patients previously positive for antibody to this antigen (HBsAb) is called reverse seroconversion, a rare complication after hematopoietic stem cell transplantation (HSCT), which occurs almost exclusively after HSCT from an HBsAb-negative donor and the development of chronic graft-versus-host disease (CGVHD). However, we experienced a patient who developed reverse seroconversion 23 months after unrelated HSCT even in the absence of immunosuppressants use or CGVHD. Serum immunoglobulin level was persistently normal. Therefore, all HBsAb-positive recipients should be considered to be at risk for HBV reactivation, even in patients without any risk factors.
収録刊行物
-
- Hematology
-
Hematology 14 (2), 73-75, 2009-04
Informa UK Limited
